Procter & Gamble Health Limited (PGHL.NS)
INR 5167.3
(-1.04%)
INR 5167.3
(-1.04%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -2.34 Billion INR | 44.5% |
| 2022 | -4.23 Billion INR | -33.64% |
| 2021 | -3.16 Billion INR | 30.64% |
| 2020 | -4.56 Billion INR | 28.58% |
| 2019 | -6.39 Billion INR | 48.31% |
| 2018 | -12.36 Billion INR | -356.17% |
| 2017 | -2.71 Billion INR | 2.95% |
| 2016 | -2.79 Billion INR | -50.02% |
| 2015 | -1.86 Billion INR | -14.35% |
| 2014 | -1.62 Billion INR | 12.68% |
| 2013 | -1.86 Billion INR | 2.71% |
| 2012 | -1.91 Billion INR | -69.15% |
| 2011 | -1.13 Billion INR | 20.66% |
| 2010 | -1.42 Billion INR | 56.02% |
| 2009 | -3.24 Billion INR | -75.7% |
| 2008 | -1.84 Billion INR | -58.04% |
| 2007 | -1.16 Billion INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 FY | -2.34 Billion INR | 44.5% |
| 2023 Q4 | -2.34 Billion INR | -155.17% |
| 2023 Q1 | 4.35 Billion INR | 202.84% |
| 2023 Q2 | -4.14 Billion INR | -195.34% |
| 2023 Q3 | 4.25 Billion INR | 202.6% |
| 2022 Q1 | 3.19 Billion INR | 200.89% |
| 2022 FY | -4.23 Billion INR | -33.64% |
| 2022 Q3 | 4.11 Billion INR | 204.78% |
| 2022 Q4 | -4.23 Billion INR | -202.86% |
| 2022 Q2 | -3.92 Billion INR | -222.89% |
| 2021 Q4 | -3.16 Billion INR | -245.5% |
| 2021 Q3 | 2.17 Billion INR | 202.41% |
| 2021 Q2 | -2.12 Billion INR | -145.78% |
| 2021 FY | -3.16 Billion INR | 30.64% |
| 2021 Q1 | 4.64 Billion INR | 201.67% |
| 2020 Q2 | -3.29 Billion INR | -151.56% |
| 2020 Q3 | 3.43 Billion INR | 204.33% |
| 2020 Q4 | -4.56 Billion INR | -232.77% |
| 2020 FY | -4.56 Billion INR | 28.58% |
| 2020 Q1 | 6.39 Billion INR | 200.53% |
| 2019 Q4 | -6.35 Billion INR | 0.0% |
| 2019 FY | -6.39 Billion INR | 48.31% |
| 2019 Q1 | 4.26 Billion INR | 200.0% |
| 2018 Q1 | 3.77 Billion INR | 230.68% |
| 2018 FY | -12.36 Billion INR | -356.17% |
| 2018 Q2 | -12.36 Billion INR | -427.84% |
| 2018 Q4 | -4.26 Billion INR | -134.29% |
| 2018 Q3 | 12.43 Billion INR | 200.57% |
| 2017 Q1 | 3.12 Billion INR | 226.47% |
| 2017 FY | -2.71 Billion INR | 2.95% |
| 2017 Q4 | -2.88 Billion INR | -182.89% |
| 2017 Q2 | -2.71 Billion INR | -186.61% |
| 2017 Q3 | 3.48 Billion INR | 228.45% |
| 2016 Q3 | 3.07 Billion INR | 209.94% |
| 2016 Q4 | -2.47 Billion INR | -180.58% |
| 2016 FY | -2.79 Billion INR | -50.02% |
| 2016 Q2 | -2.79 Billion INR | 0.0% |
| 2015 FY | -1.86 Billion INR | -14.35% |
| 2015 Q4 | -2.32 Billion INR | -200.82% |
| 2015 Q3 | 2.3 Billion INR | 225.06% |
| 2015 Q2 | -1.84 Billion INR | -196.74% |
| 2015 Q1 | 1.9 Billion INR | 217.59% |
| 2014 Q3 | 1.87 Billion INR | 215.38% |
| 2014 Q2 | -1.62 Billion INR | -178.05% |
| 2014 Q1 | 2.08 Billion INR | 216.29% |
| 2014 FY | -1.62 Billion INR | 12.68% |
| 2014 Q4 | -1.62 Billion INR | -186.34% |
| 2013 Q3 | 2.11 Billion INR | 213.71% |
| 2013 Q1 | 2.09 Billion INR | 214.28% |
| 2013 FY | -1.86 Billion INR | 2.71% |
| 2013 Q2 | -1.86 Billion INR | -189.12% |
| 2013 Q4 | -1.79 Billion INR | -184.6% |
| 2012 FY | -1.91 Billion INR | -69.15% |
| 2012 Q2 | -1.91 Billion INR | 0.0% |
| 2012 Q3 | - INR | 100.0% |
| 2012 Q4 | -1.83 Billion INR | 0.0% |
| 2011 FY | -1.13 Billion INR | 20.66% |
| 2011 Q2 | -1.13 Billion INR | 0.0% |
| 2011 Q4 | -2.79 Billion INR | 0.0% |
| 2010 FY | -1.42 Billion INR | 56.02% |
| 2009 FY | -3.24 Billion INR | -75.7% |
| 2008 FY | -1.84 Billion INR | -58.04% |
| 2007 FY | -1.16 Billion INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 160.736% |
| Hester Biosciences Limited | 2.29 Billion INR | 202.5% |
| Aarti Drugs Limited | 5.54 Billion INR | 142.319% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 189.896% |
| Albert David Limited | -278.36 Million INR | -743.485% |
| Alembic Limited | 66.9 Million INR | 3609.716% |
| Alkem Laboratories Limited | -1.6 Billion INR | -45.893% |
| Bafna Pharmaceuticals Limited | 229.93 Million INR | 1121.167% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 171.174% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | -12629.047% |
| Brooks Laboratories Limited | 49.48 Million INR | 4844.872% |
| Eris Lifesciences Limited | 13.8 Billion INR | 117.007% |
| FDC Limited | -57.75 Million INR | -3965.66% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 17.401% |
| Gufic Biosciences Limited | 3.19 Billion INR | 173.506% |
| Hikal Limited | 7.96 Billion INR | 129.472% |
| Ind-Swift Limited | 9.5 Billion INR | 124.693% |
| Innova Captab Limited | 2.33 Billion INR | 200.61% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | -113.203% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | -68.929% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 108.673% |
| Lincoln Pharmaceuticals Limited | -127.63 Million INR | -1739.578% |
| Lupin Limited | 19.38 Billion INR | 112.113% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 340.62% |
| Medico Remedies Limited | 78.67 Million INR | 3084.354% |
| Morepen Laboratories Limited | -231.17 Million INR | -915.685% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 138.134% |
| Orchid Pharma Limited | -1.31 Billion INR | -78.712% |
| RPG Life Sciences Limited | -364.7 Million INR | -543.817% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | 2056.031% |
| Sigachi Industries Limited | 859.94 Million INR | 373.039% |
| Solara Active Pharma Sciences Limited | 10.03 Billion INR | 123.406% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | 1719.578% |
| Themis Medicare Limited | 764.96 Million INR | 406.943% |
| Unichem Laboratories Limited | 931.91 Million INR | 351.954% |
| Vaishali Pharma Limited | 119.13 Million INR | 2070.873% |
| Wanbury Limited | 1.1 Billion INR | 312.321% |
| Windlas Biotech Limited | -273.04 Million INR | -759.947% |
| ZIM Laboratories Limited | 983.6 Million INR | 338.714% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 43.463% |
| Ipca Laboratories Limited | 11.41 Billion INR | 120.569% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 96.76% |
| Venus Remedies Limited | -267.7 Million INR | -777.101% |
| Sakar Healthcare Limited | 790.93 Million INR | 396.863% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 163.575% |
| Divi's Laboratories Limited | -39.77 Billion INR | 94.096% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 53.157% |
| Mankind Pharma Limited | -1.74 Billion INR | -34.298% |
| Sequent Scientific Limited | 4.17 Billion INR | 156.191% |
| Laurus Labs Limited | 24.35 Billion INR | 109.64% |
| Neuland Laboratories Limited | -214.05 Million INR | -996.899% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 183.227% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 45.208% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 160.02% |
| Amrutanjan Health Care Limited | -248.79 Million INR | -843.76% |
| Wockhardt Limited | 18.27 Billion INR | 112.852% |
| Bal Pharma Limited | 1.26 Billion INR | 285.824% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 118.183% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | -102.807% |
| Par Drugs and Chemicals Limited | -366.53 Million INR | -540.587% |
| Caplin Point Laboratories Limited | -5.5 Billion INR | 57.369% |
| Shilpa Medicare Limited | 9.06 Billion INR | 125.889% |
| Valiant Laboratories Limited | 649.9 Million INR | 461.285% |
| Ajanta Pharma Limited | -954.9 Million INR | -145.89% |
| Aarey Drugs & Pharmaceuticals Limited | 297.57 Million INR | 889.033% |
| Granules India Limited | 9.28 Billion INR | 125.283% |
| Medicamen Biotech Limited | 160.31 Million INR | 1564.607% |
| Syncom Formulations (India) Limited | 46.21 Million INR | 5181.041% |
| Piramal Enterprises Limited | 491.39 Billion INR | 100.478% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 107.377% |
| NATCO Pharma Limited | -5.81 Billion INR | 59.636% |
| Suven Life Sciences Limited | -1.63 Billion INR | -43.811% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 221.474% |
| Strides Pharma Science Limited | 23.25 Billion INR | 110.096% |
| Indoco Remedies Limited | 6.47 Billion INR | 136.255% |
| Alpa Laboratories Limited | 35.36 Million INR | 6739.708% |
| Lasa Supergenerics Limited | 205.79 Million INR | 1240.919% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | -149.31% |